Please login to the form below

Not currently logged in
Email:
Password:

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

Will launch Herzuma in seven European countries including the UK and Germany

mundipharmaMundipharma has strengthened its partnership with biopharmaceutical group Celltrion Healthcare by securing rights to its trastuzumab biosimilar.

As per terms of the deal, Mundipharma - a global network of privately owned independent companies - has acquired distribution and marketing rights in seven European countries for Herzuma (trastuzumab), a biosimilar of Roche’s blockbuster Herceptin.

The biosimilar was granted marketing authorisation last month following a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for HER-2-positive early breast cancer in the neo-adjuvant and adjuvant setting.

Additionally Herzuma was also recommended for patients with metastatic breast cancer and metastatic gastric cancer in adults.

Commenting on the partnership, Man Hoon Kim, president and CEO of Celltrion Healthcare, said: “We are pleased to be partnering once again with Mundipharma on the commercialisation of our trastuzumab biosimilar.

“They have a proven track record of launching biosimilars in Europe, working effectively across multiple healthcare systems and demonstrating local in-market expertise.”

This will be the third biosimilar Mundipharma and Celltrion has launched in the EU, following Remsima (infliximab) and Truxima (rituximab), biosimilars of Johnson and Johnson’s Remicade and Roche’s MabThera.

Richard Trollope, commercial head of oncology and biosimilars at Mundipharma, said: “Celltrion Healthcare’s decision to entrust us with a third biosimilar from their portfolio is a testament to the insight and experience we have developed from successfully launching two previous monoclonal antibody biosimilars.

“With Remsima, we achieved market leading status in the majority of our markets, and we are already seeing strong market uptake with our newest biosimilar medicine Truxima across those markets where we have distribution rights.”

Meanwhile, both Johnson and Johnson and Roche are feeling the sting from the biosimilar onslaught, with analysts predicting the latter will see its blockbuster Herceptin take a 9% drop in sales this year.

Article by
Gemma Jones

20th March 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics